Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDX-301 with or without Plerixafor for Allogeneic Stem Cell Mobilization
NCT02200380Phase 2Terminated
- Sponsor
- Celldex Therapeutics
- Start
- Jul 2014
- Primary completion
- Mar 2016
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant Flt3L in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), Chronic Myeloid Leukemia (CML), non-Hodgkin lymphoma (NHL), sponsored by Celldex Therapeutics. Started Jul 2014; status: terminated.
02
Drugs
recombinant Flt3L
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)Chronic Myeloid Leukemia (CML)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT02200380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02200380.